Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China - Summary - MDSpire

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

  • By

  • Honghong Yang

  • Qing Yu

  • Mei Li

  • Min Liu

  • June 9, 2026

  • 0 min

Share

Objective:

Emphasize the significance of addressing INRs in the context of HIV treatment.

Key Findings:
  • Add specific statistical significance values for each finding.
Interpretation:

Mention implications for clinical practice regarding ART regimen switching.

Limitations:
  • Expand on potential confounding factors not controlled in the study.
Conclusion:

Reiterate the need for further research to validate the findings.

Original Source(s)

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

  • by Honghong Yang, Qing Yu, Mei Li, Min Liu

  • June 9, 2026

Related Content

A qualitative exploration of menstrual management practices and the impact of menstruation on the livelihoods of female sex workers in a peri-urban area of western Kenya

I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action

Anti-NMDAR and anti-MOG antibody double-positive encephalitis temporally associated with cytomegalovirus detection in cerebrospinal fluid: a case report